Trial results for a new medicine to treat Alzheimer’s disease have been described as a historic breakthrough and an unequivocal win for those with Alzheimer’s – but these claims are overblown on the evidence so far, says clarewilsonmed
. Its developer, Japanese firm Eisai, has even said the results “prove” the hypothesis that the disease is caused by a build-up of a protein called amyloid in the brain.
If so, the drug would seem more effective than it really is. We can’t know whether this happened until the results are published in full in a peer-reviewed journal. Eisai says it plans to apply for regulatory approval for lecanemab in the US, Europe and Japan by March next year. In the UK, there would be a further hurdle: the treatment would only be offered through health services if its benefits are calculated to outweigh its costs. This is by no means certain for what could be a difference in symptoms so small that those affected and their families wouldn’t even notice it.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
A breakthrough drug slows Alzheimer’s progression in major clinical trialThe success of Lecanemab is not just a boost for the treatment but also the amyloid hypothesis that explains the progression of the disease.
Leer más »
Alzheimer’s drug shows promise in early results of studyThe drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.
Leer más »
Biogen stock increases as Alzheimer's drug shows promise in early results of studyEisai announced results from a global study of nearly 1,800 people with early-stage Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.
Leer más »
Alzheimer's drug shows promise in early results of studyJapan's Eisai Co. said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. abc15
Leer más »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Leer más »
Analysis: Alzheimer's drug trial breakthrough boost for Roche, Eli LillyThe results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.
Leer más »